Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-infected Thai children (Q30406745)

21 June 2017

title

Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-infected Thai children (English)

1 reference

21 June 2017

0 references

Wanatpreeya Phongsamart

1

1 reference

21 June 2017

Virat Sirisanthana

2

1 reference

21 June 2017

Orasri Wittawatmongkol

3

1 reference

21 June 2017

Alan Maleesatharn

4

1 reference

21 June 2017

Tavitiya Sudjaritruk

5

1 reference

21 June 2017

Pimpannada Chearskul

6

1 reference

21 June 2017

Linda Aurpibul

7

1 reference

21 June 2017

Thira Sirisanthana

8

1 reference

21 June 2017

Kulkanya Chokephaibulkit

9

1 reference

21 June 2017

language of work or name

English

0 references

publication date

3 September 2011

1 reference

21 June 2017

1 reference

21 June 2017

volume

29

1 reference

21 June 2017

issue

47

1 reference

21 June 2017

page(s)

8705-8711

1 reference

Paediatric mortality related to pandemic influenza A H1N1 infection in England: an observational population-based study

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Pandemic influenza A (H1N1) outbreak among 15 school-aged HIV-1-infected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Clinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: a Spanish multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Pandemic (H1N1) 2009: a clinical spectrum in the general paediatric population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Severe 2009 pandemic influenza A (H1N1) infection and increased mortality in patients with late and advanced HIV disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Response to a monovalent 2009 influenza A (H1N1) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Editorial commentary: Perspectives on the role of immunization against influenza in HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Humoral and Cellular Response to Influenza Vaccine in HIV-Infected Children With Full Viroimmunologic Response to Antiretroviral Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Safety and immunogenicity of influenza vaccination in individuals infected with HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

A novel influenza A (H1N1) vaccine in various age groups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Serological response to the 2009 pandemic influenza A (H1N1) virus for disease diagnosis and estimating the infection rate in Thai population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Pandemic flu: a comparative evaluation of clinical, laboratory, and radiographic findings in HIV-positive and negative children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Response to influenza virus vaccination in vertical HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Absence of cross-reactive antibodies to influenza A (H1N1) 2009 before and after vaccination with 2009 Southern Hemisphere seasonal trivalent influenza vaccine in children aged 6 months-9 years: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

Inactivated trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.101

10.1016/J.VACCINE.2011.08.101

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference